Wedbush analyst Robert Driscoll raised the firm’s price target on Cullinan Therapeutics (CGEM) to $34 from $25 and keeps an Outperform rating on the shares. The firm notes the company presented initial clinical data for FLT3 x CD3 bispecific CLN-049 in patients with relapsed or refractory acute myeloid leukemia. Cullinan noted that all but one CRS events were Grade 1/2, and most occurred at step up dose, with no discontinuations reported.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Buy Rating for Cullinan Management Driven by Promising CLN-049 Clinical Data and Strategic Development Plan
- Promising Outlook for Cullinan Management: Buy Rating Backed by Strong Therapeutic Developments and Financial Position
- Optimistic Buy Rating for Cullinan Management Driven by Promising CLN-049 Therapy Results
- Cullinan Therapeutics Presents Promising CLN-049 Data
- Cullinan Therapeutics shares updated clinical data from Phase 1 study of CLN-049